Alnylam Pharmaceuticals, Inc. (ALNY) News

Alnylam Pharmaceuticals, Inc. (ALNY): $136.41

-1.90 (-1.37%)

POWR Rating

Component Grades













Add ALNY to Watchlist
Sign Up

Industry: Biotech


of 459

in industry

Filter ALNY News Items

ALNY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALNY News Highlights

  • For ALNY, its 30 day story count is now at 75.
  • Over the past 28 days, the trend for ALNY's stories per day has been choppy and unclear. It has oscillated between 1 and 22.
  • DRUG, RNA and NVS are the most mentioned tickers in articles about ALNY.

Latest ALNY News From Around the Web

Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors

WATERTOWN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR ), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of John Maraganore, Ph.D. to its Board of Directors. Dr. Maraganore joins Kymera''s Board after having led Alnylam Pharmaceuticals as founding CEO and Director and transformed the field of RNA therapeutics for the last nearly 20 years. "John has been a true pioneer and an inspiration for the whole biotech industry. As founding CEO of Alnylam, he has built one of the most successful biotech companies, evolving RNA therapeutics into a commercial stage therapeutic reality for patients around the globe." said Nello Mainolfi, P...

Benzinga | January 18, 2022

Former Alnylam CEO Maraganore joins Kymera Therapeutics board

Former Alnylam Pharmaceuticals CEO John Maraganore, considered a pioneer of RNA therapeutics, has joined the board of Kymera Therapeutics.

Seeking Alpha | January 18, 2022

Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting

CAMBRIDGE, Mass., January 14, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 18-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, at the Société Francophone du Nerf Périphérique (SFNP) Annual Meeting. The meeting will be held January 21-22 in Pa

Yahoo | January 14, 2022

Alnylam Pharmaceuticals (ALNY) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 12, 2022

Alnylam Pharma (ALNY) Gets a Hold Rating from BMO Capital

In a report released today, Gary Nachman from BMO Capital maintained a Hold rating on Alnylam Pharma (ALNY – Research Report), with a price target of $180.00. The company's shares closed last Tuesday at $146.96. According to, Nachman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.4% and a 40.7% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Pacira Pharmaceuticals, and Ionis Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $215.35 average price target, which is a 42.

Brian Anderson on TipRanks | January 11, 2022

Alnylam Sees FY Non-GAAP Operating Loss To Be Substantially Improved

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) said that it expects its full year 2021 non-GAAP operating loss to be substantially improved relative to the prior year. As of on December 31, 2021, Alnylam had preliminary cash, cash equivalents, and marketable securities of about $2.4 billion, compared to $1.9 billion at December 31, 2020.

Business Insider Markets | January 9, 2022

Alnylam’s CEO Is Ready to Take Over From a Biotech Legend

(Bloomberg) -- Yvonne Greenstreet was sitting on a plane at Boston Logan International Airport waiting to take off in 2018 when U.S. regulators approved Alnylam Pharmaceuticals Inc.’s first drug, Onpattro. The chief operating officer grabbed her carry-on from the overhead bin, ran off the plane and bolted to the office so she could celebrate the accomplishment with her colleagues. Most Read from BloombergCypriot Scientist Says Deltacron Covid Variant Isn’t ErrorWorld’s Biggest Crypto Fortune Beg

Yahoo | January 9, 2022

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates

CAMBRIDGE, Mass., January 09, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2021 global net product revenues for ONPATTRO, GIVLAARI and OXLUMO and provided additional updates on the products’ commercial launches.

Yahoo | January 9, 2022

Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies

Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.

Yahoo | January 7, 2022

3 Can't-Miss Biotech Events Coming Up in 2022

Here's why you'll want to keep both eyes open for upcoming announcements from Alnylam Pharmaceuticals (NASDAQ: ALNY), Intercept Pharmaceuticals (NASDAQ: ICPT), and Karuna Therapeutics (NASDAQ: KRTX). Shares of Alnylam recently slipped around 15% overnight in response to a surprising clinical-trial flop for a drug it isn't even developing. Recently, BridgeBio Pharma told investors that people with heart damage caused by transthyretin amyloidosis (ATTR) who received acoramidis failed to outperform the placebo group on the six-minute walking test.

Yahoo | January 7, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5499 seconds.